Oxford Biomedica PLC

AGM Information • May 29, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4975A

Oxford Biomedica PLC

29 May 2019

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London. 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

·      Resolution 12: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;

·      Resolution 13: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and

·      Resolution 14: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com

Certified copies of the document setting out the above resolutions passed at the 2019 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (24 May 2019) there were 68,928,847 ordinary shares in issue, each carrying one vote per share.

Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld*	Total votes cast	Result
Ordinary resolutions
1	26,128,255	74	9,660	1,440	45,237	26,139,429	Passed
2	24,809,196	74	9,660	1,365,178	557	26,184,108	Passed
3	25,883,062	74	9,660	285,720	6,150	26,178,516	Passed
4	26,046,456	74	9,660	121,237	7,239	26,177,427	Passed
5	26,046,389	74	9,660	121,304	7,239	26,177,427	Passed
6	26,060,761	74	9,660	108,021	6,150	26,178,516	Passed
7	24,938,310	74	9,660	887,698	348,924	25,835,742	Passed
8	26,059,432	74	9,660	108,261	7,239	26,177,427	Passed
9	26,060,787	74	9,660	107,995	6,150	26,178,516	Passed
10	26,171,417	74	9,660	2,650	865	26,183,801	Passed
11	25,425,808	74	9,660	649,226	99,898	26,084,768	Passed
Special resolutions
12	25,737,271	74	9,660	338,597	99,064	26,085,602	Passed
13	25,737,113	74	9,660	338,729	99,090	26,085,576	Passed
14	25,554,287	74	9,660	620,379	266	26,184,400	Passed

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

-Ends-

Enquiries:
Oxford Biomedica plc John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR Sarah MacLeod, Head of Communications	T: +44 (0)1865 783 000 T: +44 (0)1865 783 000 T: +44 (0)1865 954 161 / E: ir@oxb.com T: +44 (0)7747 602 739 / E: media@oxb.com
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	T: +44 (0)20 3709 5700

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSEIFEUFUSESI